AI Transparency Report
Cure Diabetes Inc. appears to be a very small, nascent organization with limited financial activity. In its latest filing (2023), it reported $21,087 in revenue against $21,211 in expenses, resulting in a slight deficit. Its assets are minimal at $146, with liabilities of $260. The organization has consistently reported 0% officer compensation across all three filings, which is a positive indicator of resource allocation directly to the mission rather than executive pay. However, the overall scale of operations is extremely small, suggesting a very limited programmatic reach at this stage.
The financial health is fragile given the minimal assets and the slight operational deficit in the most recent year. While the lack of executive compensation is commendable for transparency and efficiency, the organization's ability to sustain and grow its mission with such limited resources and a history of very low revenue (e.g., $1 in 2021) is a significant concern. Its spending efficiency is difficult to fully assess without a detailed breakdown of the $21,211 in expenses, but the absence of officer compensation suggests a lean operational model at the top.
Transparency is good in terms of officer compensation reporting, but the overall financial picture indicates an organization that is still in its very early stages of development and fundraising. Donors should be aware of its extremely limited financial capacity and operational history when considering support. The significant jump in revenue from $552 in 2022 to $21,087 in 2023, while still small, shows some growth, but it's too early to determine long-term stability or impact.